CAR-T– tag –
-
Cracking the Cost Code: Cellares’ Automated Platform Targets 75% Reduction in CAR-T Manufacturing, Pinpointing Viral Vectors as Key Driver
IntuitionLabs USA Overview A new analysis highlights viral vectors as the primary cost driver in CAR-T cell therapy manufacturing, prompting an urgent need for more efficient production. While existing closed-system platforms offer incre... -
Cell Therapy Consumables Market Set for $7.53 Billion Surge by 2032, Fueled by Automation and Closed Systems
Credence Research India Overview A new report from Credence Research projects the global cell therapy consumables market will reach $7.53 billion by 2032. This significant growth is primarily driven by the expanding adoption of advanced ... -
Liv Hospital Highlights Off-the-Shelf Allogeneic CAR-T Manufacturing for Enhanced Accessibility via Standardized Donor Cells
Liv Hospital Turkey Overview Liv Hospital is championing the development of allogeneic CAR-T cell manufacturing as an 'off-the-shelf' solution, leveraging standardized donor cells to significantly improve treatment accessibility. This ad... -
Leading CDMOs Lonza, Samsung Biologics, Charles River Laboratories Spearhead Viral Vector Production, Legend Biotech Drives CAR-T Commercialization
GENE ONLINE|News & Opinion. Blog USA Overview Lonza, Samsung Biologics, and Charles River Laboratories are leading the complex viral vector manufacturing essential for scaling cell and gene therapies (CGTs), while Legend Biotech is drivi... -
CAR-T Cell Therapy Established for Specific B-Cell Lymphomas/Leukemias, but Product Differentiation and Individualized Adaptation Crucial
Regenex Asia Singapore Overview CAR-T cell therapy is firmly established for specific B-cell lymphomas and leukemias, but its clinical utility hinges on aligning individual products with appropriate disease settings due to varying target... -
Fate Therapeutics Executives Sell Shares Post-FDA IND Approval for Next-Gen Autoimmune CAR-T Candidate FT839, Market Anticipates Basket Trial Success
TipRanks USA Overview Fate Therapeutics executives engaged in significant insider stock sales following news of the U.S. FDA's Investigational New Drug (IND) approval for FT839, its next-generation off-the-shelf CAR-T candidate for autoi... -
Real-World Data Evaluates Incidence and Management of Cytokine Release Syndrome and Neurotoxicity Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel CAR-T Cell Therapy Across 87 U.S. Centers
PubMed (Center for International Blood and Marrow Transplant Research) USA Overview The Center for International Blood and Marrow Transplant Research (CIBMTR) conducted a real-world data analysis of 927 B-cell malignancy patients across ... -
CREATE Medicines Expands Targeted In Vivo CAR Platform via Monash University Partnership, Driving Cell-Type-Specific Delivery with Advanced LNP Technology
BioSpace Australia Overview CREATE Medicines has expanded its targeted in vivo CAR platform through a strategic research collaboration and exclusive license agreement with Monash University. This partnership leverages targeted lipid nano... -
CAR-T Cell Therapy for Multiple Myeloma: Real-World Data Validates Enduring Efficacy with 33% Five-Year Progression-Free Survival
Liv Hospital Turkey Overview Real-world data on CAR-T cell therapy for multiple myeloma reveals 33% of patients remained progression-free for five years after a single infusion. This robust evidence also showed an encouraging 66% progres... -
Analysis Group Study: Early CAR-T Therapy Ciltacabtagene Autoleucel Achieves 98.0% Overall Response Rate with Favorable Real-World Outcomes in Relapsed/Refractory Multiple Myeloma
Analysis Group USA Overview An Analysis Group study revealed that early-line CAR-T cell therapy, ciltacabtagene autoleucel (cilta-cel), demonstrated favorable real-world outcomes in relapsed or refractory multiple myeloma (RRMM) patients...
